AstraZeneca and Revna Biosciences Broaden Access to Lung Cancer Treatment in Ghana
Thursday, July 31, 2025
AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care in Ghana through their ongoing collaboration. Since announcing their partnership in April 2025, both organisations have worked together to enhance the patient journey—from early diagnosis and molecular testing to access to modern treatments.
A key milestone in this effort was the introduction of a targeted therapy in Ghana for patients with EGFR-mutated lung cancer. This step marks an important advancement in their shared goal of making innovative cancer therapies more accessible across sub-Saharan Africa.
The partnership is helping to address long-standing gaps in access to advanced molecular diagnostics and treatment in the region. By combining diagnostic capabilities, data systems, and new treatment approaches, the two companies aim to raise the standard of cancer care for patients who have historically had limited options.
Progress has been made in several areas:
- Improving Oncology Services: A lung cancer symposium and training session was organised to help pathologists and oncology specialists adopt advanced diagnostic tools and protocols for lung cancer care.
- Streamlining Clinical Processes: EGFR biomarker testing has been introduced into the diagnostic process at major cancer centres. This supports more accurate treatment selection at the time of diagnosis.
- Increasing Patient Access: A new system has been built to connect molecular diagnostic results with appropriate personalised treatments, helping patients begin therapy more quickly.
- Building for the Future: Real-time data integration has been set up to support clinical decision-making and provide a foundation for ongoing research into molecular profiles, treatment effectiveness, and resistance patterns in the region.
Through this partnership, AstraZeneca and Revna Biosciences are working to deliver meaningful improvements in cancer care by aligning science, infrastructure, and local expertise.
Source: businesswire.com
